Contributions
Abstract: P356
Type: Poster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Data regarding infertility diagnosis and treatment in women with multiple sclerosis (MS) compared with women without MS are lacking. This study compared the prevalence of infertility and infertility treatments administered to women with and without MS based on US retrospective commercial claims analysis.
Methods: IMS Health Real World Data Adjudicated Claims - US data were used to identify a cohort of US women with MS (ICD-9-CM diagnosis code: 340.xx), aged 18-55, with a minimum of 1 year continuous insurance eligibility from 1/1/2006 to 31/12/2015. The number of women with MS meeting the eligibility criteria was 117,041. A comparator group of women without MS was also selected (n=1,422,836). Exact matching was used to control for baseline age, geographic region and index year quarter. Rates of infertility diagnosis, infertility treatments and live birth between the matched samples (n=96,937 in each group) were compared. Infertility treatments that were evaluated included oral infertility medications (clomiphene and/or letrozole), injectable medications for controlled ovarian stimulation (COS), defined as ≥1 gonadotropin (Gn) and an ovulation trigger, either human chorionic Gn or Gn-releasing hormone (GnRH) agonist, and other infertility treatments (Gn without trigger or GnRH antagonists).
Results: The mean (standard deviation) duration of follow-up available was 3.77 (2.36) years for women with MS and 3.82 (2.43) years for women without MS. A greater proportion of women with MS had a diagnosis of infertility compared with women without MS (8.52% vs 8.08%; p=0.0006). A lower proportion of women with MS used any infertility treatment compared with women without MS (1.01% vs 1.19%; p=0.0002). Of patients receiving infertility treatments, over half received oral infertility medications without Gn (MS 54.9% vs non-MS 54.8%); the remainder received injectable COS medications (MS 22.9% vs non-MS 25.0%) or other treatments (MS 22.3% vs non-MS 20.2%). The proportion of women using each of the individual infertility treatments was significantly lower in women with MS compared with women without MS (p< 0.05), except for GnRH antagonists. The rate of live birth was lower in women with MS than in women without MS (5.00% vs 6.98%; p< 0.0001).
Conclusions: Women with MS were more likely to have a diagnosis of infertility, were less likely to use infertility treatments and were less likely to have a live birth compared with women without MS.
Disclosure:
MKH received funding support from EMD Serono, Inc.*; received support for service on scientific advisory boards from Biogen, Genzyme Sanofi, Teva Neuroscience and Novartis; and received research support from Genzyme Sanofi.
NCE is an employee of Health Services Consulting Corporation. Health Services Consulting Corporation received funding from EMD Serono, Inc.* to run the analysis.
BH and ALP are employees of EMD Serono, Inc.,* Rockland, MA, USA. *A business of Merck KGaA, Darmstadt, Germany.
Abstract: P356
Type: Poster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Data regarding infertility diagnosis and treatment in women with multiple sclerosis (MS) compared with women without MS are lacking. This study compared the prevalence of infertility and infertility treatments administered to women with and without MS based on US retrospective commercial claims analysis.
Methods: IMS Health Real World Data Adjudicated Claims - US data were used to identify a cohort of US women with MS (ICD-9-CM diagnosis code: 340.xx), aged 18-55, with a minimum of 1 year continuous insurance eligibility from 1/1/2006 to 31/12/2015. The number of women with MS meeting the eligibility criteria was 117,041. A comparator group of women without MS was also selected (n=1,422,836). Exact matching was used to control for baseline age, geographic region and index year quarter. Rates of infertility diagnosis, infertility treatments and live birth between the matched samples (n=96,937 in each group) were compared. Infertility treatments that were evaluated included oral infertility medications (clomiphene and/or letrozole), injectable medications for controlled ovarian stimulation (COS), defined as ≥1 gonadotropin (Gn) and an ovulation trigger, either human chorionic Gn or Gn-releasing hormone (GnRH) agonist, and other infertility treatments (Gn without trigger or GnRH antagonists).
Results: The mean (standard deviation) duration of follow-up available was 3.77 (2.36) years for women with MS and 3.82 (2.43) years for women without MS. A greater proportion of women with MS had a diagnosis of infertility compared with women without MS (8.52% vs 8.08%; p=0.0006). A lower proportion of women with MS used any infertility treatment compared with women without MS (1.01% vs 1.19%; p=0.0002). Of patients receiving infertility treatments, over half received oral infertility medications without Gn (MS 54.9% vs non-MS 54.8%); the remainder received injectable COS medications (MS 22.9% vs non-MS 25.0%) or other treatments (MS 22.3% vs non-MS 20.2%). The proportion of women using each of the individual infertility treatments was significantly lower in women with MS compared with women without MS (p< 0.05), except for GnRH antagonists. The rate of live birth was lower in women with MS than in women without MS (5.00% vs 6.98%; p< 0.0001).
Conclusions: Women with MS were more likely to have a diagnosis of infertility, were less likely to use infertility treatments and were less likely to have a live birth compared with women without MS.
Disclosure:
MKH received funding support from EMD Serono, Inc.*; received support for service on scientific advisory boards from Biogen, Genzyme Sanofi, Teva Neuroscience and Novartis; and received research support from Genzyme Sanofi.
NCE is an employee of Health Services Consulting Corporation. Health Services Consulting Corporation received funding from EMD Serono, Inc.* to run the analysis.
BH and ALP are employees of EMD Serono, Inc.,* Rockland, MA, USA. *A business of Merck KGaA, Darmstadt, Germany.